You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PPMS

Showing 1 - 25 of 104
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ocrelizumab on Cortical Lesion Accumulation in PPMS

Not yet recruiting
  • Primary Progressive Multiple Sclerosis
  • Ocrelizumab
  • (no location specified)
Aug 2, 2023

Ocrelizumab on Choroid Plexus Changes in Patients With PPMS

Not yet recruiting
  • Primary Progressive Multiple Sclerosis
  • Ocrelizumab
  • Buffalo, New York
    Buffalo Neuroimaging Analysis Center
Jul 26, 2023

Primary Progressive Multiple Sclerosis Trial in Israel, Moldova, Republic of (GA Depot 40mg once monthly, GA Depot 25mg once

Recruiting
  • Primary Progressive Multiple Sclerosis
  • GA Depot 40mg once monthly
  • GA Depot 25mg once monthly
  • Haifa, Israel
  • +6 more
Oct 30, 2022

Multiple Sclerosis, Primary Progressive Trial in Bordeaux, Limoges, Poitiers (Clinical assessment, Ecological evaluation,

Recruiting
  • Multiple Sclerosis, Primary Progressive
  • Clinical assessment
  • +4 more
  • Bordeaux, France
  • +2 more
Mar 31, 2022

Primary Progressive Multiple Sclerosis, Exercise, Cardiorespiratory Fitness Trial in Valens (HIIT, MCT)

Recruiting
  • Primary Progressive Multiple Sclerosis
  • +2 more
  • HIIT
  • MCT
  • Valens, Sankt Gallen, Switzerland
    Klinik Valens, Valens rehabilitation clinic
Jun 9, 2022

Primary Progressive Multiple Sclerosis Trial in Durham (DUOC-01)

Recruiting
  • Primary Progressive Multiple Sclerosis
  • DUOC-01
  • Durham, North Carolina
    Duke University Medical Center
Jan 25, 2022

Progressive Multiple Sclerosis Trial in Thessaloniki (Early Harvest Extra Virgin Olive Oil)

Completed
  • Progressive Multiple Sclerosis
  • Early Harvest Extra Virgin Olive Oil
  • Thessaloniki, Macedonia, Greece
    A' Department of Neurology,Aristotle University of Thessaloniki
Jul 4, 2021

Multiple Sclerosis, Primary Progressive Trial in Calgary (Hydroxychloroquine)

Completed
  • Multiple Sclerosis, Primary Progressive
  • Calgary, Alberta, Canada
    MS Clinic Foothills Medical Centre
Jul 28, 2021

Imaging Interplay Between Axonal Damage and Repair in Multiple

Recruiting
  • Multiple Sclerosis (MS)
  • +3 more
  • MRI
  • +2 more
  • Basel, Switzerland
    University Hospital Basel, Department of Neurology
Dec 15, 2021

Relapsing Multiple Sclerorsis, Multiple Sclerosis, Primary Progressive Trial in Worldwide (Ocrelizumab, Lumbar Puncture,

Active, not recruiting
  • Relapsing Multiple Sclerorsis
  • Multiple Sclerosis, Primary Progressive
  • Palo Alto, California
  • +16 more
Jul 26, 2022

Gray Matter Demyelination in Primary Progressive MS at 7T

Recruiting
  • Primary Progressive Multiple Sclerosis
    • Hvidovre, Denmark
      Danish Research Centre for Magnetic Resonance
    Jun 5, 2022

    MSRV-Env Burden in Patients With Multiple Sclerosis Disease

    Completed
    • Multiple Sclerosis (MS)
    • +4 more
    • No study treatments administered - blood draws only
    • Bron cedex, France
    • +3 more
    Oct 19, 2020

    Ocrelizumab in Relapsing or Primary Progressive Multiple

    Active, not recruiting
    • Multiple Sclerosis
    • Amstetten, Austria
    • +164 more
    Aug 22, 2022

    Multiple Sclerosis Trial in United States (Ocrelizumab Dose 1, Ocrelizumab Dose 2 and Dose 3)

    Completed
    Has Results
    • Multiple Sclerosis
    • Ocrelizumab Dose 1
    • Ocrelizumab Dose 2 and Dose 3
    • Aurora, Colorado
    • +4 more
    Jun 12, 2020

    Ocrelizumab Access by Socio-Economic Status

    Not yet recruiting
    • Multiple Sclerosis
    • Boston, Massachusetts
      Brigham and Women's Hospital
    Nov 22, 2021

    Primary Progressive Multiple Sclerosis Trial in Worldwide (Placebo, Laquinimod)

    Completed
    Has Results
    • Primary Progressive Multiple Sclerosis
    • Phoenix, Arizona
    • +98 more
    Mar 9, 2022

    Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis Trial in Australia, Canada, United States

    Active, not recruiting
    • Primary Progressive Multiple Sclerosis
    • Secondary Progressive Multiple Sclerosis
    • ATA188
    • Placebo
    • La Jolla, California
    • +33 more
    Jul 21, 2022

    Primary Progressive Multiple Sclerosis the MURDOCK Study

    Completed
    • Primary Progressive Multiple Sclerosis
    • generation of 'omic markers of disease progression
    • Concord, North Carolina
    • +2 more
    May 26, 2021

    Multiple Sclerosis Trial in Worldwide (Ocrelizumab, Antihistamine, Methylprednisolone)

    Recruiting
    • Multiple Sclerosis
    • Homewood, Alabama
    • +211 more
    Jan 13, 2023

    The Gut Microbiome in Adult Multiple Sclerosis

    Completed
    • Multiple Sclerosis
      • Jette, Brussel-Hoofdstedelijk-Gewest, Belgium
      • +1 more
      Jul 16, 2021

      Upper Extremity Function in Multiple Sclerosis Advanced

      Active, not recruiting
      • Multiple Sclerosis
      • +7 more
      • Tampa, Florida
        Carol and Frank Morsani Center for Advanced Healthcare
      Nov 2, 2022

      Multimodal Evoked Potentials for Predicting Disease Progression

      Active, not recruiting
      • Multiple Sclerosis
      • multimodal evoked potentials (mmEP)
      • Basel, Switzerland
      • +2 more
      Nov 2, 2021

      Nursing Caries Trial (Occulus quest 2 virtual reality glasses)

      Not yet recruiting
      • Nursing Caries
      • Occulus quest 2 virtual reality glasses
      • (no location specified)
      Oct 6, 2023

      Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis Trial in Dublin (Fampridine, Placebo)

      Completed
      Has Results
      • Secondary Progressive Multiple Sclerosis
      • Primary Progressive Multiple Sclerosis
      • Dublin, Dublin 4, Ireland
      • +1 more
      Jul 8, 2021

      Multiple Sclerosis Trial in New York (Intrathecal MSC-NP injection, Intrathecal saline injection)

      Active, not recruiting
      • Multiple Sclerosis
      • Intrathecal MSC-NP injection
      • Intrathecal saline injection
      • New York, New York
        Tisch MS Research Center of New York
      Oct 25, 2022